ArticleJournal of Alzheimer's disease : JAD2018
Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome.
Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 80 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease
Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome
Who cites it
80 citing papers in PubMed, 4 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Early Markers for Dementia in the Intellectual Disability Population: A Systematic Literature Review.Journal of applied research in intellectual disabilities : JARID · 2025Pooled it
- Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.JAMA network open · 2022Pooled it
- Neurologic complications of Down syndrome: a systematic review.Journal of neurology · 2021Pooled it
- The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population.Scientific reports · 2021Trial
- APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Death in People with Down syndrome: Mortality statistics and novel predictors in US Medicaid and Medicare enrolled adults.medRxiv : the preprint server for health sciences · 2026Article
- Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Determinants of Healthcare Costs in Individuals With Down Syndrome: A Systematic Review.Health science reports · 2026Review
- 'Name It to Tame It': Dementia Diagnostic Procedure in Austrian Care Facilities for People With Intellectual Disabilities. An Interview Study.Journal of intellectual disability research : JIDR · 2026Article
- Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Factors impacting survival in individuals with Down syndrome-associated Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Baseline Neuropsychological Characteristics of Adolescents and Young Adults with Down Syndrome Who Participated in Two Clinical Trials of the Drug Memantine.Brain sciences · 2025Article
- Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Factors Associated With Alzheimer's Dementia Diagnosis and Survival in Down Syndrome.Journal of intellectual disability research : JIDR · 2025Article
- What Guides Organizations' Current Dementia-Related Practices Across Four Canadian Provinces?International journal of environmental research and public health · 2025Article
- Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- What Can We Learn About Alzheimer's Disease from People with Down Syndrome?Current topics in behavioral neurosciences · 2025Review
- Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Observational
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 12 institutions in 2 countries.
Funding
Abstract
backgroundPeople with Down syndrome (DS) are an ultra-high risk population for Alzheimer's disease (AD). Understanding the factors associated with age of onset and survival in this population could highlight factors associated with modulation of the amyloid cascade.
objectiveThis study aimed to establish the typical age at diagnosis and survival associated with AD in DS and the risk factors associated with these.
methodsData was obtained from the Aging with Down Syndrome and Intellectual Disabilities (ADSID) research database, consisting of data extracted from clinical records of patients seen by Community Intellectual Disability Services (CIDS) in England. Survival times when considering different risk factors were calculated.
resultsThe mean age of diagnosis was 55.80 years, SD 6.29. Median survival time after diagnosis was 3.78 years, and median age at death was approximately 60 years. Survival time was associated with age of diagnosis, severity of intellectual disability, living status, anti-dementia medication status, and history of epilepsy. Age at diagnosis and treatment status remained predictive of survival time following adjustment.
conclusionThis study provides the best estimate of survival in dementia within the DS population to date, and is in keeping with previous estimates from smaller studies in the DS population. This study provides important estimates and insights into possible predictors of survival and age of diagnosis of AD in adults with DS, which will inform selection of participants for treatment trials in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.